Square Pharmaceuticals (DHA:SQURPHARMA) Other Net Income (Loss) : BDT2,666 Mil (TTM As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Square Pharmaceuticals Other Net Income (Loss)?

Square Pharmaceuticals's Other Net Income (Loss) for the three months ended in Dec. 2023 was BDT653 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 was BDT2,666 Mil.

Square Pharmaceuticals's quarterly Other Net Income (Loss) declined from Jun. 2023 (BDT1,231 Mil) to Sep. 2023 (BDT360 Mil) but then increased from Sep. 2023 (BDT360 Mil) to Dec. 2023 (BDT653 Mil).

Square Pharmaceuticals's annual Other Net Income (Loss) increased from Jun. 2021 (BDT1,291 Mil) to Jun. 2022 (BDT2,011 Mil) and increased from Jun. 2022 (BDT2,011 Mil) to Jun. 2023 (BDT2,523 Mil).

Square Pharmaceuticals Other Net Income (Loss) Historical Data

The historical data trend for Square Pharmaceuticals's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Square Pharmaceuticals Other Net Income (Loss) Chart

Square Pharmaceuticals Annual Data

Trend

Mar14

Mar15

Mar16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Other Net Income (Loss)

Get a 7-Day Free Trial

931.71

586.24

1,291.21

2,010.81

2,522.51

Square Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Net Income (Loss)	Get a 7-Day Free Trial															516.12	422.40	1,231.12	360.06	652.56

Square Pharmaceuticals Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was BDT2,666 Mil.

Square Pharmaceuticals Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Square Pharmaceuticals's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Square Pharmaceuticals (DHA:SQURPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Square Pharmaceuticals PLC (DHA:SQURPHARMA) » Definitions » Other Net Income (Loss)

Traded in Other Exchanges

N/A

Address

Square Centre, 48, Mohakhali Commercial Area, Dhaka, BGD, 1212

Website

http://www.squarepharma.com.bd

Square Pharmaceuticals PLC is a Bangladesh-based pharmaceutical company engaged in the manufacturing and marketing of generic pharmaceuticals products, Basic chemical products, and animal health products. It manufactures drugs like paracetamol, clotrimazole, antiallergic, Nitroglycerin, xylometazoline HCl, erythromycin, and various other drugs. The company operates in Bangladesh and sells its products locally and internationally. The company operates in one segment, which is the business of developing, manufacturing, and marketing drugs.

Square Pharmaceuticals (DHA:SQURPHARMA) Headlines

No Headlines